Sotos syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:821OMIM:618677Q87.3
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Sotos syndrome, also known as cerebral gigantism, is a genetic overgrowth disorder characterized by excessive physical growth during the first years of life, distinctive facial features, and varying degrees of intellectual disability. The condition was first described by Dr. Juan Sotos in 1964. It is caused by mutations or deletions in the NSD1 gene (nuclear receptor binding SET domain protein 1) located on chromosome 5q35, which plays a critical role in regulating gene expression during development. The hallmark features of Sotos syndrome include pre- and postnatal overgrowth with increased height and head circumference (macrocephaly), a characteristic facial gestalt that includes a broad and prominent forehead, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, a long and narrow face, and a pointed chin. Advanced bone age is a consistent finding. Affected individuals typically experience developmental delay, particularly in motor and speech milestones, and intellectual disability that ranges from mild to severe, though some individuals have normal intelligence. Additional features may include hypotonia, behavioral problems (including features of autism spectrum disorder, anxiety, and ADHD), seizures, cardiac anomalies, renal anomalies, scoliosis, and an increased risk of certain tumors in childhood, though the overall cancer risk remains relatively low. There is no cure for Sotos syndrome, and management is supportive and symptom-based. Early intervention programs including speech therapy, occupational therapy, and physical therapy are important for optimizing developmental outcomes. Regular monitoring for potential complications such as scoliosis, cardiac defects, renal abnormalities, and seizures is recommended. Behavioral and educational support is often beneficial. Genetic counseling is advised for affected families, as most cases arise from de novo mutations, though autosomal dominant transmission from an affected parent can occur.

Also known as:

Clinical phenotype terms— hover any for plain English:

Agenesis of permanent teethHP:0006349Generalized non-motor (absence) seizureHP:0002121Enlarged cisterna magnaHP:0002280
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Sotos syndrome.

View clinical trials →

No actively recruiting trials found for Sotos syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Sotos syndrome community →

Specialists

2 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Sotos syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Sotos syndromeForum →

No community posts yet. Be the first to share your experience with Sotos syndrome.

Start the conversation →

Latest news about Sotos syndrome

No recent news articles for Sotos syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Sotos syndrome

What is Sotos syndrome?

Sotos syndrome, also known as cerebral gigantism, is a genetic overgrowth disorder characterized by excessive physical growth during the first years of life, distinctive facial features, and varying degrees of intellectual disability. The condition was first described by Dr. Juan Sotos in 1964. It is caused by mutations or deletions in the NSD1 gene (nuclear receptor binding SET domain protein 1) located on chromosome 5q35, which plays a critical role in regulating gene expression during development. The hallmark features of Sotos syndrome include pre- and postnatal overgrowth with increased

How is Sotos syndrome inherited?

Sotos syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Sotos syndrome typically begin?

Typical onset of Sotos syndrome is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Sotos syndrome?

2 specialists and care centers treating Sotos syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.